Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 12INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 10Breast Neoplasms 9Prostatic Neoplasms 7Multiple Myeloma 6Colorectal Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms by Site 2Mycoses 2Medication Adherence 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Transitional Cell 2COVID-19 2Adenocarcinoma 2Uveal Melanoma 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1

Interventions

pembrolizumab 40Gemcitabine 37Cisplatin 28Carboplatin 17enfortumab vedotin 15Nivolumab 15Mitomycin 14atezolizumab 13avelumab 12Docetaxel 10vinflunine 95-aminolevulinic acid hexyl ester 9apaziquone 8Paclitaxel 8BCG Vaccine 7durvalumab 6Fluorouracil 6Cystectomy 6sacituzumab govitecan 4Surgical Procedures, Operative 4Drug Therapy 4vofatamab 3valrubicin 3tisotumab vedotin 3erdafitinib 3cemiplimab 3belinostat 3Therapeutic Uses 3Ramucirumab 3Cystoscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Urinary Bladder Neoplasms × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡